RE:RE:RE:RE:RE:RE:Very encouraging, but approval will take time Money IS the issue!!!!!
We thought we had a great CEO with very "high" "important" connections with PFE! For them it is "pennies, nickels and dimes" to invest in TH's possible cure for some cancers..........!!!!!
How long are they telling us they are in negotiations with possible partners?????
Hilarious but really sad and a pitty for those who suffer from that horrible disease.......:-(
SPCEO1 - (6/13/2023 12:25:25 PM)
RE:RE:RE:RE:RE:Very encouraging, but approval will take time
Based on Juniper 88's comment and what you heard, I ithink biopsies were likely given to all patients, including my cousin and she just never mentioned it. But if biopsies were given to all, then should they not know the sortilin overexpression for each? Money is defintely an issue for THTX. I suspect the hope is they see some early success with the six initial patients, announce that and then raise new equity capital and/or sign a partnership deal on the back of that. If they don't see early success, then it might get a bit more difficult on the cash front, depending on sales success from the legacy drugs. If THTX knows they have something with TH-1902, then they could opt to raise money by selling rights to the legacy drugs future revenues - see what OMER did with its lone drug to raise money to keep funding it research on bigger and better drugs in its pipeline. If you ask me, if they can get proof of concept, it seems TH-1902 should be partnered with a large drug company with the financial resources to exploit it in a more fully and in a more timely manner. But that is just my not-fully informed opinion and is based not as much as a shareholdere but as a fellow human being wanting cancer sufferers to get as much help as they can as soon as they can.